GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer

被引：18

作者：

Alakus, H. ^{[1
]}

Warnecke-Eberz, U. ^{[1
]}

Bollschweiler, E. ^{[1
]}

Moenig, S. P. ^{[1
]}

Vallboehmer, D. ^{[1
]}

Brabender, J. ^{[1
]}

Drebber, U. ^{[2
]}

Baldus, S. E. ^{[3
]}

Riemann, K. ^{[4
]}

Siffert, W. ^{[4
]}

Hoelscher, A. H. ^{[1
]}

Metzger, R. ^{[1
]}

机构：

[1] Univ Hosp Cologne, Ctr Integrated Oncol, Dept Gen Visceral & Canc Surg, D-50937 Cologne, Germany

[2] Univ Cologne, Inst Pathol, D-5000 Cologne, Germany

[3] Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany

[4] Univ Hosp Essen, Inst Pharmacogenet, Essen, Germany

来源：

PHARMACOGENOMICS JOURNAL | 2009年 / 9卷 / 03期

关键词：

SNP; multimodality treatment; G protein; esophageal cancer; CELL LUNG-CANCER; TUMOR-REGRESSION; MULTIMODALITY THERAPY; GASTRIC-CARCINOMA; DOWN-REGULATION; GENE GNAS1; G-PROTEIN; SURVIVAL; APOPTOSIS; SURGERY;

D O I：

10.1038/tpj.2009.5

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors. In this study, we genotyped 51 patients from an observational trial on cisplatin/5-FU-based neoadjuvant radiochemotherapy of locally advanced esophageal cancer (cT2-4, Nx, M0) and genotyping was correlated with histomorphological tumor regression. The C-allele frequency in esophageal cancer patients was 0.49. Pearson's chi(2)-test showed a significant (P<0.05) association between tumor regression grades and T393C genotypes. Overall, 63% of the patients in the T-allele group (TT + CT) were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%. The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer. The Pharmacogenomics Journal (2009) 9, 202 - 207; doi:10.1038/tpj.2009.5; published online 10 March 2009

引用

页码：202 / 207

页数：6

共 46 条

[1]

Adelstein DJ, 1997, CANCER-AM CANCER SOC, V80, P1011

[2] Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: Criteria of the histopathological evaluation [J].

Baldus S.E. ;

Mönig S.P. ;

Schröder W. ;

Metzger R. ;

Lang S. ;

Zirbes T.K. ;

Thiele J. ;

Müller R.P. ;

Dienes H.P. ;

Hölscher A.H. ;

Schneider P.M. .

Der Pathologe, 2004, 25 (6) :421-427

[3]

Bancewicz J, 2002, LANCET, V359, P1727

[4]

Bollschweiler E, 2001, CANCER, V92, P549, DOI 10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO

[5]

2-L

[6] Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma:: results of a prospective phase-II trial [J].

Brücher, BLDM ;

Stein, HJ ;

Zimmermann, F ;

Werner, M ;

Sarbia, M ;

Busch, R ;

Dittler, HJ ;

Molls, M ;

Fink, U ;

Siewert, JR .

EJSO, 2004, 30 (09) :963-971

[7] Thyroid carcinoma in the McCune-Albright syndrome:: Contributory role of activating Gsα mutations [J].

Collins, MT ;

Sarlis, NJ ;

Merino, MJ ;

Monroe, J ;

Crawford, SE ;

Krakoff, JA ;

Guthrie, LC ;

Bonat, S ;

Robey, PG ;

Shenker, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4413-4417

[8]

Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO

[9]

2-U

[10] CISPLATIN RESISTANCE IN MOUSE FIBROSARCOMA CELLS AFTER LOW-DOSE IRRADIATION IN-VITRO AND IN-VIVO [J].

EICHHOLTZWIRTH, H ;

HIETEL, B .

BRITISH JOURNAL OF CANCER, 1994, 70 (04) :579-584

← 1 2 3 4 5 →